alex spira, md, phd, facp, discusses the mechanism of action of amivantamab (jnj-6372)
Published 3 years ago • 395 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
1:37
alex spira, md, phd, facp, shares thoughts on the phase i chrysalis study presented at esmo 2020
-
0:50
alexander spira, md, phd, facp, on managing lung cancer patients in a community setting
-
0:44
physician spotlight: alex spira, m.d., phd, f.a.c.p., medical oncologist
-
1:40
alex spira, md, phd, facp, offers thoughts on the four-year follow-up to the phase iii pacific trial
-
1:05
alex spira, md, phd, facp, on the practice-changing potential of the adaura study from esmo 2020
-
32:33
filling simon hill's gaps re: optimal apob, blood pressure and fasting insulin goals kidney health
-
4:53
amivantamab 和 sotorasib 用于治疗非小细胞肺癌 - amivantamab & sotorasib as treatments for nsclc - mandarin lcvl
-
14:55
advances in diagnosing lung cancer
-
0:34
alexander spira, md, phd, facp, on the recent approval of atezolizumab in sclc
-
1:16
dr. alexander spira discusses advances in non-small cell lung cancer (nsclc)
-
8:11
amivantamab
-
1:46
the evolving treatment landscape for nsclc with egfr exon 20 insertion mutations
-
3:28
bispecific antibodies in lung cancer
-
4:45
amivantamab and mobocertinib: side effects and treatment timing - lung cancer
-
16:22
novel combinations in egfr positive advanced nsclc
-
2:45
phase i study of cc-98633 in r/r multiple myeloma
-
32:51
diffuse cystic lung disease
-
5:47
dr avi spira: janssen's use of new technology to intercept lung cancer.
-
25:56
evaluating new advances in idiopathic pulmonary fibrosis and other interstitial lung diseases
-
1:24:26
assessing the impact of therapeutic advances in sclc
-
4:30
interview with avrum e. spira, m.d., m.sc.
-
1:24
how many people have ipf?